AXL and metabolic dysfunction-associated steatotic liver disease: Since our present results reveal the presence of serum sAXL as an early marker of MASLD, even before fibrosis detection, we wanted to evaluate if AXL inhibition could be effective in protecting the liver as soon as serum sAXL started increasing.